CD276 and neoplasm: When including a positivity cutoff of 1+ B7-H3 expression, 14 out of 24 treated patients (58%) demonstrated B7-H3 detectable on all of their tumor cells, 17 out of 24 (71%) demonstrated B7-H3 on at least 95% of their tumor cells, 21 out of 24 (88%) demonstrated B7-H3 on at least 90% of their tumor cells, and all patients demonstrated B7-H3 detectable on at least 70% of their tumor cells.